Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer.

Dario P Anobile Iris Chiara Salaroglio Fabrizio Tabbò Sofia La Vecchia Muhlis Akman Francesca Napoli Maristella Bungaro Federica Benso Elisabetta Aldieri Paolo Bironzo Joanna Kopecka Francesco Passiglia Luisella Righi Silvia Novello Giorgio Vittorio Scagliotti Chiara Riganti

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our work unveils that 17-β-estradiol/ERα status predicts the response to pembrolizumab in NSCLC patients. Secondly, we propose aromatase inhibitors as new gender-tailored immune-adjuvants in NSCLC.

Keyphrases

estrogen receptor
small cell lung cancer
advanced non small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
mental health
patient reported